NEW YORK, April 2 – Dutch proteomics company Glaucus Proteomics has entered into a deal to gain access to Medarex’ and Genmab’s antibody technology in exchange for novel targets and shared rights to future therapeutic products, the companies said Monday.

“We provide the antibody technology to Glaucus and they are going to find diagnostics and research uses for antibodies. And using their antibody reporter matrix they will find new disease targets that we can make antibodies against,” Lisa Drakeman, CEO of Genmab, told GenomeWeb.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.